UAM | UAM_Biblioteca | Unified search engine | Scientific Production Portal | UAM Research Data Repository
Biblos-e Archivo
    • español
    • English
  • English 
    • español
    • English
  • Log in
JavaScript is disabled for your browser. Some features of this site may not work without it.

Search Biblos-e Archivo

Advanced Search

Browse

All of Biblos-e ArchivoCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsFacultiesThis CollectionBy Issue DateAuthorsTitlesSubjectsFaculties

My Account

Log inRegister

Statistics

View Usage Statistics

Help

Information about Biblos-e ArchivoI want to submit my workFrequently Asked Questions

UAM_Biblioteca

View Item 
  •   Biblos-e Archivo
  • 1 - Producción científica en acceso abierto de la UAM
  • Producción científica en acceso abierto de la UAM
  • View Item
  •   Biblos-e Archivo
  • 1 - Producción científica en acceso abierto de la UAM
  • Producción científica en acceso abierto de la UAM
  • View Item

A european multicentre and open-label controlled randomized trial to evaluate the efficacy of sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: The STARMEN study

Author
Rojas-Rivera, Jorge; Fernández-Juárez, Gema; Ortiz Arduán, Albertountranslated; Hofstra, Julia; Gesualdo, Loreto; Tesar, Vladimir; Wetzels, Jack; Segarra, Alfons; Egido, Jesus; Praga, Manuel
Entity
UAM. Departamento de Medicina; Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD)
Publisher
Oxford University Press
Date
2015-01-01
Citation
10.1093/ckj/sfv075
Clinical Kidney Journal 8.5 (2015): 503-510
 
 
 
ISSN
2048-8505 (print); 2048-8513 (on line)
DOI
10.1093/ckj/sfv075
Funded by
This is an investigator-initiated RCT that has been up to now funded by the European Renal Association (Research Programme, ERA-EDTA), the Instituto de Salud Carlos III (Spanish Government) through specific research projects (FIS 13/02502 and ICI14/00350) and the Spanish Renal Research Network (REDINREN, RD 012/0021).
Project
Gobierno de España. FIS 13/02502; Gobierno de España. ICI14/00350
Editor's Version
http://dx.doi.org/10.1093/ckj/sfv075
Subjects
Biomarker; Immunosuppression; Membranous nephropathy; Nephrotic syndrome; Randomized controlled trial; Medicina
URI
http://hdl.handle.net/10486/672108
Rights
© The Author 2015

Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.

Abstract

Background: Patients with primary membranous nephropathy (MN) and persistent nephrotic syndrome have a high risk of progression to end-stage renal disease. The Ponticelli protocol (steroids with alkylating agents) is the most effective immunosuppressive therapy for this condition, but it has severe adverse effects. Tacrolimus and rituximab have demonstrated efficacy for remission of nephrotic syndrome in MN with a safer profile. However, the published evidence is largely based on small or short-term observational studies, historical cohorts, comparisons with conservative therapy or clinical trials without appropriate control groups, and there is no head-to-head comparison with the Ponticelli protocol. Methods: The STARMEN randomized clinical trial will compare the efficacy of sequential tacrolimus–rituximab therapy with a modified Ponticelli protocol (steroids plus cyclophosphamide). The trial will also evaluate the role of antibodies against the Mtype phospholipaseA2 receptor (anti-PLA2R) and other antibodies as markers of response to treatment and long-term prognosis Results: The trial has already started with 23 patients having been enrolled as of 1 April 2015, an estimated 21.7% of the estimated sample
Show full item record

Files in this item

Thumbnail
Name
european_rojas_CKJ_2015.pdf
Size
530.6Kb
Format
PDF

Refworks Export

Google™ Scholar:Rojas-Rivera, Jorge - Fernández-Juárez, Gema - Ortiz Arduán, Alberto - Hofstra, Julia - Gesualdo, Loreto - Tesar, Vladimir - Wetzels, Jack - Segarra, Alfons - Egido, Jesus - Praga, Manuel

This item appears in the following Collection(s)

  • Producción científica en acceso abierto de la UAM [18077]

Related items

Showing items related by title, author, creator and subject.

  • Recent clinical trials insights into the treatment of primary membranous nephropathy 

    Rojas-Rivera, Jorge; Fervenza, Fernando C.; Ortiz Arduán, AlbertoAutoridad UAM
    2021-12-21
  • Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal 

    Rojas-Rivera, Jorge Enrique; Carriazo, Sol; Ortiz Arduán, AlbertoAutoridad UAM
    2019
  • Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial 

    Diago-Sempere, Elena; Bueno, José Luis; Sancho-López, Aránzazu; Muñez-Rubio, Elena; Torres, Ferrán; Malo de Molina, Rosa; Fernández-Cruz, Ana; Salcedo de Diego, IsabelAutoridad UAM; Velasco-Iglesias, Ana; Payares-Herrera, Concepción; Casas Flecha, Inmaculada; Avendaño Solá, CristinaAutoridad UAM; Duarte Palomino, RafaelAutoridad UAM; Ramos Martínez, AntonioAutoridad UAM; Ruiz-Antorán, Belén
    2021-01-20
All the documents from Biblos-e Archivo are protected by copyrights. Some rights reserved.
Universidad Autónoma de Madrid. Biblioteca
Contact Us | Send Feedback
We are onFacebookCanal BiblosYouTubeTwitterPinterestWhatsappInstagram

Declaración de accesibilidad

 

 

All the documents from Biblos-e Archivo are protected by copyrights. Some rights reserved.
Universidad Autónoma de Madrid. Biblioteca
Contact Us | Send Feedback
We are onFacebookCanal BiblosYouTubeTwitterPinterestWhatsappInstagram

Declaración de accesibilidad